CCA
HARP

Catalyst Capital Advisors’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Catalyst Capital Advisors’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-47
Closed -$6K – 438
2019
Q3 		$6K Hold
47
– – ﹤0.01% 390
2019
Q2 		$6K Hold
47
– – ﹤0.01% 383
2019
Q1 		$4K Buy
+47
New +$6.18K ﹤0.01% 377

Other funds holding HARP

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Catalyst Capital Advisors's HARP Position: Q4 2019 in Review

Catalyst Capital Advisors sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q4 2019, closing a stake of 47 shares — an estimated $6K sold.

Catalyst Capital Advisors first reported a position in HARP in Q1 2019 and held it in 3 quarters. The position peaked at $6K in Q3 2019. 50 funds tracked by Wall St. Rank hold HARP as of Q4 2019.

  • Catalyst Capital Advisors reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 47 Harpoon Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $6K.
  • Catalyst Capital Advisors first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 3 quarters.
  • Catalyst Capital Advisors's Harpoon Therapeutics, Inc. Common Stock position peaked at $6K in Q3 2019.
  • 50 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Catalyst Capital Advisors's 13F filing for Q4 2019, filed 6 Feb 2020.